A director at HealthCare Global Enterprises Ltd sold 14,000 shares at 535.000INR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Q3FY20 result highlights Revenues grew by 12% yoy to Rs2.78bn below est of Rs2.86bn with HCG centres posting 12% growth yoy. Milann centres grew 8.6% yoy. EBITDA stood higher at Rs457m. Adjusting for Ind AS 116 impact, adj. EBITDA stood at Rs300m vs est of Rs306m. Adj. EBITDAM stood inline at 10.8% (vs 11.7% in Q2). Overall, the new centres (commissioned since FY16) generated higher adj. EBITDA loss of 118m vs loss of Rs92m for Q2FY20. Existing centre adj. EBITDA stood at Rs419m (vs Rs417m i...
Q2FY20 result highlights Revenues grew by 14% yoy to Rs2.79bn below est of Rs2.85bn with HCG centres posting 13% growth yoy. Milann centres grew 18% yoy. EBITDA stood higher at Rs456m. Adjusting for Ind AS 116 impact, adj. EBITDA stood at Rs326m vs est of Rs351m. Adj. EBITDAM stood lower at 11.7% (vs 11.3% in Q1) vs our est of 12.3%. Overall, the new centres (commissioned since FY16) generated higher adj. EBITDA loss of 92m vs loss of Rs90m for Q1FY20. Existing centre adj. EBITDA stood at Rs...
Q4FY19 result highlights Revenues grew by 16% yoy to Rs2.58bn below est with the HCG centres posting 18% growth yoy. Milann centres de-grew by -6.8% yoy. EBITDA stood higher at Rs322mn (flat yoy) vs est of Rs310mn. Margins stood lower at 12.5% (vs 11.6% in Q3) vs our est of 11.1%. Overall, the new centres (commissioned since FY16) generated higher EBITDA loss of 22mn vs loss of Rs48mn for Q3FY19. Existing centre EBITDA stood at Rs344mn (vs Rs337mn in Q3FY19). Interest cost was lower at Rs1...
Event TPG capital has sold its chain of cancer treatment hospitals, Cancer Treatment Services International (CTSI) to US entity Varian Medial Systems for $283m Key Highlights CTSI has a network of 11 hospitals with a pipeline of 6 more assets across India / South Asia; It had one hospital 3 years back – operating model is similar to HCG As per Varian press release, CTSI had annual revs of ~$43m; it is expected to be EPS accretive by 2021 – implying limited (or maybe even negative profitabi...
Q3FY19 result highlights Revenues grew by 21% yoy to Rs2.5bn vs our est of Rs2.37bn with the HCG centres posting a growth of 22% yoy and Milann centres 5% yoy. EBITDA stood lower at Rs289mn (+11% yoy; -14% qoq) vs est of Rs308mn. Margins stood lower at 11.6% (vs 13.7% in Q2) vs est 13%. EBITDA was impacted by higher medical consultancy at Rs568mn (+11% qoq) and empl cost of Rs486mn (+8% qoq) vs est of Rs425mn Overall, the new centres (commissioned since FY16) generated higher EBITDA loss o...
Q4FY18 result highlights Revenues grew by 22% yoy to Rs2.22bn marginally higher than our estimate of Rs2.2bn with the HCG centres posting a growth of 21% yoy and the Milann centres growing 29% yoy. EBITDA stood higher at Rs322mn (+24 qoq) above our estimate of Rs305. Margins stood higher at 14.5% (vs 12.6% in Q3) vs our est 13.8%. Overall, the new centres (commissioned since FY16) generated lower EBITDA loss of 21mn vs loss of Rs48mn for Q3FY18. Existing centre EBITDA stood higher at R343sm...
Q2FY17 result highlights Revenues grew by 21% yoy to Rs1.7bn marginally ahead of our estimate of Rs1.71bn with the HCG centres posting a growth of 20.9% yoy and the Milann centres growing at 20.3% yoy. Reported EBITDA of Rs254mn (+26% yoy) was marginally ahead our est of Rs236 with margins of 14.6% (our est 13.8%). Excl the loss from the new centres (Rs18.4mn) the existing centres EBITDA stood at Rs272mn. Gross margins for the quarter which stood at 76.1% improved by 70bps qoq and 200bps yo...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.